A Phase 3 interventional study of Human regular U-500 insulin (CSII) and Human regular U-500 insulin (MDI) in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2015, is one of 25 in phase 3, and was the 42nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 68th largest by enrollment of the 232 interventional ones that give a count, is one of 4 that started in 2015, is one of 85 in phase 3, and was the 113th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry.
Concomitant antihyperglycemic agent (AHA) therapy may include metformin (MET), dipeptidyl peptidase-4 inhibitors and/or pioglitazone.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
Drug: Human regular U-500 insulin (CSII)
Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
Drug: Human regular U-500 insulin (MDI)
Administered SC
Also known as: LY041001
Administered SC
Also known as: LY041001
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
Time frame: Baseline, 26 Weeks
Change From Baseline in Fasting Plasma Glucose (FPG)
Fasting plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
Time frame: Baseline, 26 Weeks
Percentage of Participants With HbA1c <7.0%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.0% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
Time frame: 26 Weeks
Percentage of Participants With HbA1c <7.5%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.5% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
Time frame: 26 Weeks
Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
Time frame: Baseline, 26 Weeks
Change From Baseline in Total Daily Dose (TDD)
Baseline TDD was defined as the last prestudy insulin TDD prior to randomization to receiving the first dose of U-500 insulin post randomization. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
Time frame: Baseline, 26 Weeks
Percentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)
The percentage of participants with hypoglycemic episodes (documented hypoglycemia) was calculated by dividing the number of participants with at least 1 hypoglycemic episode (documented hypoglycemia) over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. Logistic regression was used to estimate the odds ratio between the two treatments of at least 1 hypoglycemic episode (documented hypoglycemia) over 26 week treatment period adjusted for baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
Time frame: 26 Weeks
Rate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)
Documented Hypoglycemic episodes with blood glucose\<=70mg/dL was used in this outcome measure. Hypoglycemia rate (documented hypoglycemia) per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia (documented hypoglycemia) was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, with log of exposure in days divided by 30 as the offset, treatment, visit, and visit by treatment interaction.
Time frame: Baseline to 26 Weeks
Change From Baseline in Body Weight
Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, treatment by time interaction.
Time frame: Baseline, 26 Weeks
| Milestone | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Started | 209 | 211 |
| Received at least 1 dose of study drug | 208 | 210 |
| Completed | 179 | 186 |
| Not completed | 30 | 25 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 6 |
| Withdrew: Non-compliance with study drug | 6 | 3 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Withdrawal by subject | 13 | 10 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
| Percentage of HbA1c | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -1.27 ± 0.072 | -0.85 ± 0.070 |
Fasting plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
| milligrams per deciliter (mg/dL) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -33.9 ± 5.03 | 1.7 ± 4.90 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.0% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
| Percentage of participants | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Percentage of Participants With HbA1c <7.0% | 28.65 | 18.44 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.5% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.
| Percentage of Participants | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Percentage of Participants With HbA1c <7.5% | 52.63 | 38.55 |
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
| mg/dL | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Pre Morning Meal | -34.3 ± 3.53 | -11.8 ± 3.41 |
| 2 Hours Post Morning Meal | -25.0 ± 4.58 | -7.8 ± 4.50 |
| Pre Mid-Day Meal | -19.8 ± 4.29 | -10.9 ± 4.15 |
| 2 Hours Post Mid-Day Meal | -8.3 ± 4.20 | -16.6 ± 4.08 |
| Pre Evening Meal | -15.1 ± 4.11 | -24.3 ± 3.99 |
| 2 HOURS POST EVENING MEAL | -14.6 ± 4.19 | -31.3 ± 4.02 |
| OVERNIGHT (3:00 AM) | -25.4 ± 3.71 | -26.0 ± 3.58 |
Baseline TDD was defined as the last prestudy insulin TDD prior to randomization to receiving the first dose of U-500 insulin post randomization. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
| units/day | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Change From Baseline in Total Daily Dose (TDD) | 2.8 ± 9.33 | 51.3 ± 9.14 |
The percentage of participants with hypoglycemic episodes (documented hypoglycemia) was calculated by dividing the number of participants with at least 1 hypoglycemic episode (documented hypoglycemia) over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. Logistic regression was used to estimate the odds ratio between the two treatments of at least 1 hypoglycemic episode (documented hypoglycemia) over 26 week treatment period adjusted for baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.
| Percentage of Participants | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Percentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL) | 95.69 | 95.71 |
Documented Hypoglycemic episodes with blood glucose\<=70mg/dL was used in this outcome measure. Hypoglycemia rate (documented hypoglycemia) per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia (documented hypoglycemia) was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, with log of exposure in days divided by 30 as the offset, treatment, visit, and visit by treatment interaction.
| Episodes/participant/30 days | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Rate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL) | 5.16 ± 0.380 | 4.27 ± 0.308 |
Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, treatment by time interaction.
| Kilograms (kg) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Change From Baseline in Body Weight | 4.2 ± 0.35 | 3.4 ± 0.34 |
Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Human Regular U-500 Insulin Administered by CSII | 2/209 (1%) | 34/209 (16.3%) | 85/209 (40.7%) |
| Human Regular U-500 Insulin Administered by MDI | 1/211 (0.5%) | 23/211 (10.9%) | 84/211 (39.8%) |
| Event | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 10/209 | 5/211 |
| PneumoniaInfections and infestations | 4/209 | 2/211 |
| SepsisInfections and infestations | 3/209 | 0/211 |
| Acute kidney injuryRenal and urinary disorders | 1/209 | 3/211 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/209 | 3/211 |
| Cardiac failure congestiveCardiac disorders | 2/209 | 0/211 |
| Cerebrovascular accidentNervous system disorders | 2/209 | 0/211 |
| Non-cardiac chest painGeneral disorders | 1/209 | 2/211 |
| Acute coronary syndromeCardiac disorders | 1/209 | 0/211 |
| Acute myocardial infarctionCardiac disorders | 1/209 | 0/211 |
| Event | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 17/209 | 18/211 |
| Viral upper respiratory tract infectionInfections and infestations | 11/209 | 18/211 |
| DiarrhoeaGastrointestinal disorders | 14/209 | 17/211 |
| NauseaGastrointestinal disorders | 9/209 | 17/211 |
| Weight increasedInvestigations | 14/209 | 13/211 |
| HeadacheNervous system disorders | 9/209 | 14/211 |
| SinusitisInfections and infestations | 10/209 | 13/211 |
| Back painMusculoskeletal and connective tissue disorders | 11/209 | 13/211 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/209 | 12/211 |
| HyperglycaemiaMetabolism and nutrition disorders | 11/209 | 0/211 |
All randomized participants
| Age, Continuous(years) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| Mean | 57.58 ± 10.27 | 56.66 ± 10.12 | 57.12 ± 10.19 |
| Sex: Female, Male(Participants) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| Female | 105 | 94 | 199 |
| Male | 104 | 117 | 221 |
| Ethnicity (NIH/OMB)(Participants) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 49 | 88 |
| Not Hispanic or Latino | 170 | 162 | 332 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 2 | 7 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 19 | 14 | 33 |
| White | 160 | 160 | 320 |
| More than one race | 25 | 26 | 51 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| Puerto Rico | 15 | 21 | 36 |
| United States | 194 | 190 | 384 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | Human Regular U-500 Insulin Administered by CSII | Human Regular U-500 Insulin Administered by MDI | Total |
|---|---|---|---|
| Mean | 8.75 ± 1.03 | 8.77 ± 1.08 | 8.76 ± 1.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in May 2017, 18 months.
Results were first posted in May 2020, 3 years after primary completion. A results delay was requested in May 2018.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human